Where does Novartis AG rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novartis AG ranks #230 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novartis AG hold?

Novartis AG holds 1,768 US utility patents granted between 2015 and 2025, spanning 126 technology areas.

What is Novartis AG's Innovation Score?

Novartis AG has an Innovation Score of 63.9 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novartis AG focus on?

Novartis AG's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 1,071 patents, ranking #2 of 6,058 assignees active in that subclass. Grants appear in 126 CPC subclasses total.

Is Novartis AG's patent grant rate increasing or decreasing?

Novartis AG's recent grant velocity is -57% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novartis AG's patents?

Novartis AG's patents average 15.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novartis AG patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novartis AG

USPTO PatentsView assignee record - 1,768 granted patents across 126 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novartis ranks #230 of 49,997 tracked US assignees by granted-patent volume, with 1,768 patents across 126 technology areas.

#230
of 49,997 US assignees by volume: Top 2%
by Innovation Score (63.9/100): 15.8
avg claims per patent: -57%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R230 · Foreign Corporation #230 · 1,768 grants

GRANTS-LARGE · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-LARGE 1.8K grants
TOP-DECILE #230/49,997
PHOTO-FINISH Autonetworks
CPC-WIDE A61P · 126 areas
INNOV-STRONG 63.9/100
CLAIMS-RICH 15.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -57% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Autonetworks Technologies, Ltd. (±2 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novartis’s 63.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 25.8 pts (40%) Velocity 3.6 pts (6%) Breadth 25.0 pts (39%) Claim depth 9.5 pts (15%)

Qualcomm Incorporated · highest

85
King Abdullah… · near

64
Stmicroelectronics · near

64
Novartis · this assignee

64
Yale University · near

64
Target Brands · near

64
3D Lighting… · lowest

7

What this shows Novartis's Innovation Score is 63.9/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novartis?

Each dot is one of Novartis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novartis’s own 15.8 claims/patent is at or below the 15.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Novartis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

How Novartis's grant cadence moved

Between 2020–2024, Novartis AG received 513 grants versus 1,198 in 2015–2019 (-57% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2017 at 270 grants and bottomed in 2023 at 72. Lead class A61P accounts for 60.6% of the portfolio across 126 subclasses. Volume neighbours: Citrix Systems, Inc. (#226) and Carrier Corporation (#234).

Novartis's three-year grant acceleration

From 2019–2021 to 2022–2024, Novartis AG moved from 479 to 262 grants (0.55x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,580. See the growth leaderboard.

Citrix Systems

1,793
Wistron

1,775
Netapp

1,774
Tencent America

1,774
Novartis ◀

1,768
Autonetworks

1,766
Arris Enterprises

1,761
Sumitomo Chemical

1,758
Carrier

1,756

What this shows Novartis holds 1,768 patents at rank #230, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novartis

By rank, the assignees closest to #230 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Novartis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novartis, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Novartis ranks #2 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (64 here).

Yale University 64 Target Brands, Inc. 64 Stmicroelectronics, Inc. 64 King Abdullah University of Science and Technology 64

Similar claim depth

Nearest assignees by average claims per patent (15.8 here).

Yissum Research Development Company OF THE Hebrew University OF Jerusalem Ltd. 15.8 avg Children's Hospital Medical Center 15.8 avg Semiconductor Energy Laboratory Co., Ltd. 15.8 avg Ivoclar Vivadent AG 15.7 avg

Novartis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

64 Top 2% higher than 98% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Novartis AG patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	229	13.0%
2016	253	14.3%
2017	270	15.3%
2018	218	12.3%
2019	228	12.9%
2020	131	7.4%
2021	120	6.8%
2022	97	5.5%
2023	72	4.1%
2024	93	5.3%
2025partial year	57	3.2%

Which technologies does Novartis AG patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1,071

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 988

C07D - Heterocyclic Compounds 544

C07K - Peptides 407

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 262

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 207

A61B - DIAGNOSIS; SURGERY; Identification 187

G02B - Optical Elements, Systems OR Apparatus 143

B29D - Producing Particular Articles From Plastics OR From Substances IN A Plastic State 113

Y02A - Technologies FOR Adaptation TO Climate Change 101

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 100

C07C - Acyclic OR Carbocyclic Compounds 96

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 84

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 82

G02C - SPECTACLES; Sunglasses OR Goggles Insofar AS They Have THE Same Features AS SPECTACLES; Contact Lenses 70

Top 15 of 126 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novartis AG's patent record in context - here's where to go next.

Novartis AG's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 60.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #230 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novartis AG against Citrix Systems, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 63.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.